Skip to main content
Advertisement

Main menu

  • Home
  • Content
    • Current Issue
    • Publication Preview--Ahead of Print
    • Past Issue Archive
    • Case of the Week Archive
    • Classic Case Archive
    • Case of the Month Archive
  • For Authors
  • About Us
    • About AJNR
    • Editors
    • American Society of Neuroradiology
  • Submit a Manuscript
  • Podcasts
    • Subscribe on iTunes
    • Subscribe on Stitcher
  • More
    • Subscribers
    • Permissions
    • Advertisers
    • Alerts
    • Feedback
  • Other Publications
    • ajnr

User menu

  • Subscribe
  • Alerts
  • Log in

Search

  • Advanced search
American Journal of Neuroradiology
American Journal of Neuroradiology

American Journal of Neuroradiology

  • Subscribe
  • Alerts
  • Log in

Advanced Search

  • Home
  • Content
    • Current Issue
    • Publication Preview--Ahead of Print
    • Past Issue Archive
    • Case of the Week Archive
    • Classic Case Archive
    • Case of the Month Archive
  • For Authors
  • About Us
    • About AJNR
    • Editors
    • American Society of Neuroradiology
  • Submit a Manuscript
  • Podcasts
    • Subscribe on iTunes
    • Subscribe on Stitcher
  • More
    • Subscribers
    • Permissions
    • Advertisers
    • Alerts
    • Feedback
  • Follow AJNR on Twitter
  • Visit AJNR on Facebook
  • Follow AJNR on Instagram
  • Join AJNR on LinkedIn
  • RSS Feeds

Glioblastoma in Congenital Mismatch Repair Deficiency (CMMRD) Syndrome

  • Background:
    • CMMRD is a distinct childhood cancer predisposition syndrome that results from biallelic germline mutations in 1 of the 4 MMR genes: MLH1, MSH2, MSH6, or PMS2.
    • DNA mismatch repair (MMR) deficiency is a well-characterized form of genetic instability in cancer, characterized by a failure to repair DNA replication–associated errors.
    • A defective MMR system leads to the persistence of mismatched mutations across the genome, particularly in regions of repetitive DNA (microsatellites), leading to microsatellite instability (MSI). MSI causes the production of truncated protein products, resulting in the development of life-threatening malignancies including gastrointestinal, brain, and hematologic malignancies.
  • Clinical Presentation:
    • CMMRD should be suspected in a case of childhood malignancy with a first- or second-degree relative having colorectal, endometrial, ureteric, bladder, or stomach carcinomas.
    • Important premalignancies/malignancies associated in this condition include high-grade gliomas (III or IV), supratentorial PNETs, non-Hodgkin lymphoma, leukemias, and bowel adenomas.
    • Other non-neoplastic findings include corpus callosum agenesis, café-au-lait macules, hypopigmented patches, cavernomas of the brain, capillary hemangiomas of skin, and lupus erythromatosus.
  • Key Diagnostic Features:
    • Glioblastoma can have an acute presentation with headache, seizure, and loss of consciousness when associated with a large bleed.
    • Imaging features include an ill-defined expansile lesion with mass effect that appears hypodense on CT. Associated hyperdensity due to intralesional bleed can occur.
    • MRI shows an ill-defined, T2-hyperintense, T1-hypointense lesion with heterogeneous postcontrast enhancement. There is expansion of the affected areas with mass effect. Diffusion restriction can be seen in highly cellular areas. SWI may show macro- or microbleeds characteristic of glioblastoma. Perfusion imaging shows elevated rCBV as compared with normal adjacent white matter. MRS shows elevated choline with decreased NAA.
  • Differential Diagnoses:
    • Important differentials to be considered in this case include hemorrhagic diathesis leading to intracranial hemorrhage, leukemic deposits with hemorrhage, and hemorrhagic metastases from a second unknown primary. However, the ill-defined expansile lesion with heterogeneous enhancement and bleed should prompt the diagnosis of glioblastoma.
  • Treatment:
    • Surgery for complete resection or debulking with chemotherapy and radiotherapy
    • Immunotherapy with checkpoint inhibitors is being considered a promising approach.
May 12, 2022

A 4-year-old child born of second-degree consanguineous parentage presents to the emergency department in status epilepticus; history of T-cell acute lymphoblastic leukemia diagnosed 8 months back; father had colon cancer and paternal grandmother had cervical cancer; clinical examination shows multiple hyperpigmented macules on the trunk.

View Case
  • Read more about 05122022
  • Comments
Advertisement
Subscribe to RSS - Glioblastoma in Congenital Mismatch Repair Deficiency (CMMRD) Syndrome

News and Updates

  • Lucien Levy Best Research Article Award
  • Thanks to our 2021 Distinguished Reviewers
  • Press Releases

Resources

  • Evidence-Based Medicine Level Guide
  • How to Participate in a Tweet Chat
  • AJNR Podcast Archive
  • Ideas for Publicizing Your Research
  • Librarian Resources
  • Terms and Conditions

Opportunities

  • Share Your Art in Perspectives
  • Get Peer Review Credit from Publons
  • Moderate a Tweet Chat

American Society of Neuroradiology

  • Neurographics
  • ASNR Annual Meeting
  • Fellowship Portal
  • Position Statements

© 2022 by the American Society of Neuroradiology | Print ISSN: 0195-6108 Online ISSN: 1936-959X

Powered by HighWire